Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatalanib in VHL and Hemangioblastoma
NCT00052013Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2003
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vatalanib in hemangioblastoma, von Hippel–Lindau disease (VHL), sponsored by Novartis. Started Feb 2003; status: completed.
02
Drugs
vatalanib
03
Conditions
hemangioblastomavon Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT00052013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052013.